Aldeyra Therapeutics (ALDX) News Today → Shocking: One AI startup's revenue could surge 4,735% (From Manward Press) (Ad) Free ALDX Stock Alerts $3.96 +0.01 (+0.25%) (As of 09:34 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 14, 2024 | americanbankingnews.comAldeyra Therapeutics (NASDAQ:ALDX) Lifted to "Hold" at StockNews.comMay 10, 2024 | americanbankingnews.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) to Post Q2 2024 Earnings of ($0.15) Per Share, HC Wainwright ForecastsMay 9, 2024 | marketbeat.comAldeyra Therapeutics, Inc Forecasted to Post Q2 2024 Earnings of ($0.15) Per Share (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities research analysts at HC Wainwright upped their Q2 2024 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Monday, May 6th. HC Wainwright analyst M. Caufield now expects that the biotechnoloMay 8, 2024 | marketbeat.comHC Wainwright Analysts Boost Earnings Estimates for Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at HC Wainwright upped their FY2027 EPS estimates for Aldeyra Therapeutics in a research note issued on Monday, May 6th. HC Wainwright analyst M. Caufield now forecasts that the biotechnology company will post earnings peMay 8, 2024 | businesswire.comAldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye DiseaseMay 7, 2024 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Rating Lowered by StockNews.comStockNews.com lowered Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a report on Monday.May 6, 2024 | marketbeat.comOppenheimer Reaffirms Outperform Rating for Aldeyra Therapeutics (NASDAQ:ALDX)Oppenheimer reissued an "outperform" rating and set a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Monday.May 3, 2024 | investorplace.comALDX Stock Earnings: Aldeyra Therapeutics Meets EPS for Q1 2024April 29, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 15.1% in AprilAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,360,000 shares, an increase of 15.1% from the March 31st total of 2,050,000 shares. Currently, 4.2% of the company's stock are short sold. Based on an average daily trading volume, of 584,200 shares, the days-to-cover ratio is currently 4.0 days.April 25, 2024 | businesswire.comAldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development DayApril 18, 2024 | businesswire.comAldeyra Therapeutics to Host Research & Development Day on April 25, 2024April 15, 2024 | markets.businessinsider.comAttention Long-Term Aldeyra Therapeutics, Inc. (ALDX) Investors: Grabar Law Office Is Investigating Claims on Your BehalfApril 14, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Up 12.0% in MarchAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 2,050,000 shares, a growth of 12.0% from the March 15th total of 1,830,000 shares. Based on an average trading volume of 585,700 shares, the short-interest ratio is presently 3.5 days. Currently, 3.6% of the company's shares are short sold.April 10, 2024 | investing.comPerceptive advisors buys Aldeyra Therapeutics shares worth $833kApril 9, 2024 | insidertrades.comPerceptive Advisors Llc Purchases 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockApril 8, 2024 | marketbeat.comPerceptive Advisors Llc Buys 37,712 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc acquired 37,712 shares of the stock in a transaction on Friday, April 5th. The shares were acquired at an average price of $4.74 per share, with a total value of $178,754.88. Following the purchase, the insider now owns 9,275,851 shares in the company, valued at $43,967,533.74. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.April 4, 2024 | msn.comAldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are BuyingApril 4, 2024 | insidertrades.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Perceptive Advisors Llc Acquires 8,374 SharesApril 3, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Major Shareholder Purchases $27,215.50 in StockAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) major shareholder Perceptive Advisors Llc purchased 8,374 shares of the stock in a transaction on Monday, April 1st. The shares were purchased at an average cost of $3.25 per share, for a total transaction of $27,215.50. Following the acquisition, the insider now directly owns 8,601,960 shares of the company's stock, valued at $27,956,370. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Large shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.April 3, 2024 | msn.comAldeyra gains as Oppenheimer upgrades on revised plans for lead assetApril 3, 2024 | finance.yahoo.comAldeyra's Dry Eye Disease Drug May Be on Path for FDA ApprovalApril 3, 2024 | finance.yahoo.comAldeyra Therapeutics, Inc. (NASDAQ:ALDX) Is About To Turn The CornerApril 3, 2024 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Upgraded at OppenheimerOppenheimer raised shares of Aldeyra Therapeutics from a "market perform" rating to an "outperform" rating and set a $10.00 price objective for the company in a research note on Wednesday.April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), Carisma Therapeutics (CARM) and Panbela Therapeutics (OtherPBLA)March 15, 2024 | marketbeat.comEquities Analysts Offer Predictions for Aldeyra Therapeutics, Inc's FY2028 Earnings (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Equities research analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Aldeyra Therapeutics in a research report issued to clients and investors on Tuesday, March 12th. HC Wainwright analyst M. Caufield foMarch 14, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) to Post Q1 2024 Earnings of ($0.15) Per Share, HC Wainwright ForecastsAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2024 earnings per share estimates for Aldeyra Therapeutics in a report released on Tuesday, March 12th. HC Wainwright analyst M. Caufield forecasts that the biotechnology company will post earnMarch 13, 2024 | finance.yahoo.comAldeyra Therapeutics Inc President and CEO Todd Brady Sells Company SharesMarch 13, 2024 | insidertrades.comBruce Greenberg Sells 13,201 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) StockMarch 13, 2024 | marketbeat.comHC Wainwright Comments on Aldeyra Therapeutics, Inc's FY2028 Earnings (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Research analysts at HC Wainwright issued their FY2028 earnings per share estimates for shares of Aldeyra Therapeutics in a report released on Tuesday, March 12th. HC Wainwright analyst M. Caufield anticipates that the biotechnology companyMarch 12, 2024 | marketbeat.comInsider Selling: Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Insider Sells 13,201 Shares of StockAldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) insider Bruce Greenberg sold 13,201 shares of the company's stock in a transaction on Monday, March 11th. The shares were sold at an average price of $3.41, for a total value of $45,015.41. Following the transaction, the insider now directly owns 120,699 shares in the company, valued at approximately $411,583.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.March 12, 2024 | marketbeat.comQ3 2024 Earnings Forecast for Aldeyra Therapeutics, Inc Issued By Leerink Partnrs (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Analysts at Leerink Partnrs issued their Q3 2024 earnings estimates for shares of Aldeyra Therapeutics in a report issued on Monday, March 11th. Leerink Partnrs analyst M. Goodman expects that the biotechnology company will post earnings perMarch 11, 2024 | markets.businessinsider.comStrong Buy Rating for Aldeyra Therapeutics Backed by Reproxalap Developments and Strategic PartnershipsFebruary 22, 2024 | finance.yahoo.comInstitutions own 37% of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) shares but retail investors control 37% of the companyFebruary 19, 2024 | marketbeat.comVictory Capital Management Inc. Lowers Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)Victory Capital Management Inc. trimmed its position in Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) by 78.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,930 shares of the bioFebruary 14, 2024 | cnn.comIntellia Therapeutics, Inc.February 13, 2024 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Above 50-Day Moving Average of $3.24Aldeyra Therapeutics (NASDAQ:ALDX) Stock Price Crosses Above 50-Day Moving Average of $3.24February 6, 2024 | finance.yahoo.comAldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceJanuary 31, 2024 | marketbeat.comLeerink Partnrs Weighs in on Aldeyra Therapeutics, Inc's FY2024 Earnings (NASDAQ:ALDX)Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Stock analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for Aldeyra Therapeutics in a research report issued to clients and investors on Monday, January 29th. Leerink Partnrs analyst M. Goodman now anticipates thatJanuary 31, 2024 | benzinga.comAldeyra Therapeutics Stock (NASDAQ:ALDX), Guidance and ForecastJanuary 30, 2024 | marketbeat.comAldeyra Therapeutics, Inc (NASDAQ:ALDX) Expected to Post FY2028 Earnings of $2.55 Per ShareAldeyra Therapeutics, Inc (NASDAQ:ALDX - Free Report) - Investment analysts at Leerink Partnrs issued their FY2028 EPS estimates for shares of Aldeyra Therapeutics in a research note issued on Monday, January 29th. Leerink Partnrs analyst M. Goodman expects that the biotechnology company will earJanuary 28, 2024 | seekingalpha.comWhy Aldeyra Therapeutics Is A Strong Buy: AbbVie Agreement And Reproxalap's ProspectsJanuary 20, 2024 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" at StockNews.comStockNews.com lowered shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday.January 4, 2024 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Aldeyra Therapeutics, Inc. (ALDX)January 4, 2024 | finance.yahoo.comAldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory DiseasesJanuary 4, 2024 | marketbeat.comStockNews.com Downgrades Aldeyra Therapeutics (NASDAQ:ALDX) to SellStockNews.com downgraded shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a research report on Thursday.December 31, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Aldeyra Therapeutics (ALDX)December 27, 2023 | marketbeat.comAldeyra Therapeutics (NASDAQ:ALDX) Raised to Hold at StockNews.comStockNews.com raised Aldeyra Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday.December 21, 2023 | markets.businessinsider.comOutperform Rating Affirmed on Aldeyra Therapeutics Following Positive ADX Developments and Expanding Treatment ProspectsDecember 21, 2023 | markets.businessinsider.comBuy Rating Affirmed for Aldeyra Therapeutics Amidst Clinical Advancements and Market PotentialDecember 19, 2023 | msn.comPositive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Shocking: One AI startup's revenue could surge 4,735% (Ad)Shocking: One AI Startup's Revenue Could Surge 4,735% While Nvidia gets all the attention, one small AI startup is quietly positioning itself to be the biggest winner. Click here to discover the AI chip company ALDX Media Mentions By Week ALDX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALDX News Sentiment▼0.800.42▲Average Medical News Sentiment ALDX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALDX Articles This Week▼13▲ALDX Articles Average Week Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HOWL News Today TSVT News Today ME News Today FHTX News Today IMMP News Today VERU News Today PYXS News Today CDT News Today ACIU News Today EBS News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALDX) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarUrgent Nvidia WarningAltimetryShocking: One AI startup's revenue could surge 4,735%Manward PressBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
